<DOC>
	<DOCNO>NCT01361113</DOCNO>
	<brief_summary>This study single arm phase II clinical trial 8 week daily , oral neo-adjuvant pazopanib prior nephrectomy 39 evaluable patient histologically confirm localized renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>Neoadjuvant Pazopanib Renal Cell Carcinoma</brief_title>
	<detailed_description>The primary objective study determine objective response rate Complete Response + Partial Response ( CR+PR ) associate neoadjuvant pazopanib 8 week define via RECIST1.1 . The investigator also estimate recurrence free survival ( RFS ) , specifically 1 2 year rate , recurrence define via RECIST1.1 , characterize safety issue . Finally , study also include number exploratory analysis design evaluate potential correlation RFS ; serum level cytokine angiogenesis factor ( CAF ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Age ≥ 18 year radiographic evidence nonmetastatic renal cell carcinoma Histological verification clear cell renal cell carcinoma ( Clinical stage 2 ( 7 cm ) great localize disease No evidence extranodal metastatic disease Appropriate candidate surgery ECOG Performance status 01 Adequate organ function Serum calcium , magnesium , potassium within normal limit , outside normal limit , must deem clinically insignificant Investigator . No know coagulopathy Ability read follow instruction Women childbearing potential must negative serum pregnancy test perform within 14 day prior start pazopanib treatment men woman must willing use adequate contraception . Able provide write , informed consent Blood urine sample must provide subject biomarker analysis treatment pazopanib Exclusion Criteria Known suspect allergy pazopanib Inability swallow retain oral medication Prior malignancy Exception : Subjects another malignancy diseasefree three year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . Unable unwilling discontinue use prohibit medication least 7 day prior first dose study drug duration study . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . History one cardiovascular condition within past 6 month Hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg OR diastolic blood pressure ( DBP ) ≥ 90mmHg spite optimal medical management . Evidence active bleeding bleed diathesis . Any serious and/or unstable preexist medical ( especially hepatic disease ) , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Prior major surgery trauma within 28 day prior first dose pazopanib and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . Pregnant breastfeeding ; breastfeeding may resume 14 day last dose pazopanib Prior treatment follow anticancer therapy treatment RCC : radiation therapy , surgery tumor embolization chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy Baseline QTc &gt; 480 msec clinically significant baseline ECG abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>Votrient</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Nephrectomy</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Phase II</keyword>
	<keyword>LCCC 1028</keyword>
	<keyword>Lineberger Comprehensive Cancer Center</keyword>
</DOC>